MAIA
2019
Daratumumab + Lenalidomide/Dex in Transplant-Ineligible Myeloma
In 737 patients with newly diagnosed transplant-ineligible multiple myeloma, daratumumab + lenalidomide + dexamethasone improved progression-free and overall survival compared with lenalidomide + dexamethasone.
Result
Efficacy: Progression-free survivalHR 0.56
Below 1 favours daratumumab + lenalidomide + dexamethasone, above 1 favours lenalidomide + dexamethasone.
Also reported: MRD-negative 24.2% vs 7.3%. 5-yr OS 66.3% vs 53.1% (HR 0.68).
- Subtopic
- Transplant-ineligible NDMM
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Facon T, et al. N Engl J Med. 2019;380(22):2104-2115; Facon T, et al. Lancet Oncol. 2021;22(11):1582-1596.doi 10.1056/NEJMoa1817249
Discussion & critique
Established anti-CD38 in front-line myeloma for patients ineligible for transplant. The principle has since been extended to transplant-eligible disease.